Subcutaneous Tocilizumab Versus Placebo in Combination With Disease‐Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis

2014144 citationsJournal Articlehybrid Open Access

Authors

Alan Kivitz · Altoona Center for Clinical Research

Ewa Olech · University of Nevada, Reno

Michael Borofsky · Reading Hospital

Beatriz Zazueta · CETYS Universidad

F. Navarro-Sarabia · Hospital Universitario Virgen Macarena

S. Radominski · Universidade Federal do Paraná

Joan T. Merrill

Abstract

TCZ-SC every other week had significantly greater efficacy, including ACR end points and inhibition of joint damage, compared with PBO-SC. TCZ-SC was well tolerated and its safety profile was comparable with that of previous intravenous TCZ studies.

Topics & Keywords

Rheumatoid Arthritis Research and Therapies Autoimmune and Inflammatory Disorders Research Biosimilars and Bioanalytical Methods

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Arthritis Care & Research

Volume 66, Issue 11, pp. 1653-1661

DOI: 10.1002/acr.22384

Field-Weighted Citation Impact: 11.48